Free Trial
NASDAQ:PDSB

PDS Biotechnology (PDSB) Stock Price, News & Analysis

PDS Biotechnology logo
$1.34 +0.07 (+5.20%)
Closing price 07/3/2025 03:46 PM Eastern
Extended Trading
$1.34 0.00 (-0.07%)
As of 07/3/2025 04:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About PDS Biotechnology Stock (NASDAQ:PDSB)

Key Stats

Today's Range
$1.26
$1.34
50-Day Range
$1.16
$1.79
52-Week Range
$0.85
$4.42
Volume
141,463 shs
Average Volume
474,980 shs
Market Capitalization
$61.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Buy

Company Overview

PDS Biotechnology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

PDSB MarketRank™: 

PDS Biotechnology scored higher than 47% of companies evaluated by MarketBeat, and ranked 569th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    PDS Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    PDS Biotechnology has only been the subject of 1 research reports in the past 90 days.

  • Read more about PDS Biotechnology's stock forecast and price target.
  • Earnings Growth

    Earnings for PDS Biotechnology are expected to decrease in the coming year, from ($1.20) to ($1.35) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of PDS Biotechnology is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of PDS Biotechnology is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    PDS Biotechnology has a P/B Ratio of 2.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about PDS Biotechnology's valuation and earnings.
  • Percentage of Shares Shorted

    4.79% of the float of PDS Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    PDS Biotechnology has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in PDS Biotechnology has recently decreased by 31.38%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    PDS Biotechnology does not currently pay a dividend.

  • Dividend Growth

    PDS Biotechnology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.79% of the float of PDS Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    PDS Biotechnology has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in PDS Biotechnology has recently decreased by 31.38%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    PDS Biotechnology has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for PDS Biotechnology this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for PDSB on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added PDS Biotechnology to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, PDS Biotechnology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.20% of the stock of PDS Biotechnology is held by insiders.

  • Percentage Held by Institutions

    Only 26.84% of the stock of PDS Biotechnology is held by institutions.

  • Read more about PDS Biotechnology's insider trading history.
Receive PDSB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PDS Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

PDSB Stock News Headlines

PDS Biotechnology's (PDSB) Buy Rating Reiterated at HC Wainwright
PDS Biotechnology Corporation (PDSB) - Yahoo Finance
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
See More Headlines

PDSB Stock Analysis - Frequently Asked Questions

PDS Biotechnology's stock was trading at $1.63 at the beginning of 2025. Since then, PDSB shares have decreased by 18.0% and is now trading at $1.3360.

PDS Biotechnology Corporation (NASDAQ:PDSB) announced its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.04.
Read the conference call transcript
.

Shares of PDSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PDS Biotechnology investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Adobe (ADBE), Broadcom (AVGO) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
5/14/2025
Today
7/05/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PDSB
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$13.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+573.7%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$37.61 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.51 per share
Price / Book
2.62

Miscellaneous

Free Float
41,505,000
Market Cap
$61.07 million
Optionable
Optionable
Beta
1.21
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:PDSB) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners